LGVN Q3 2022 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$18M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$265,000+14.2% YoY

Gross Profit

$92,00034.7% margin

Operating Income

-$5M-1957.4% margin

Net Income

-$5M-1978.9% margin

EPS (Diluted)

$-2.50

QoQ Revenue Growth

-43.1%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$5M

Stock-Based Comp.

$500,000

Balance Sheet

Total Assets

$31M

Total Liabilities

$6M

Stockholders' Equity

$25M

Cash & Equivalents

$14M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$265,000	$232,000	+14.2%
Gross Profit	$92,000	$164,000	-43.9%
Operating Income	-$5M	-$5M	-5.7%
Net Income	-$5M	-$5M	-8.0%